Geert Maleux1, Christophe Deroose2, Annouschka Laenen3, Chris Verslype4, Sam Heye1, Karin Haustermans5, Gert De Hertogh6, Xavier Sagaert6, Baki Topal7, Raymond Aerts7, Hans Prenen4, Dirk Vanbeckevoort1, Vincent Vandecaveye1, Eric Van Cutsem4. 1. a Department of Radiology, University Hospitals Leuven, Department of Imaging & Pathology , KU Leuven , Belgium. 2. b Department of Nuclear Medicine , University Hospitals Leuven , Belgium. 3. c Interuniversity Centre for Biostatistics and Statistical Bioinformatics, Catholic University of Leuven and University Hasselt , Belgium. 4. d Department of Gastroenterology , University Hospitals Leuven , Belgium. 5. e Department of Radiation Oncology , University Hospitals Leuven , Belgium. 6. f Department of Pathology , University Hospitals Leuven , Belgium. 7. g Department of Abdominal Surgery , University Hospitals Leuven , Belgium.
Abstract
BACKGROUND: The purpose of this study was to retrospectively assess the technical and clinical outcomes, overall survival and prognostic factors for prolonged survival after yttrium-90 ((90)Y) radioembolization as a salvage therapy for patients with chemorefractory liver-only or liver-dominant colorectal metastases. MATERIAL AND METHODS: From January 2005 to January 2014, all the patients selected for (90)Y radioembolization to treat chemorefractory colorectal liver metastases were identified. Demographic, laboratory, imaging and dosimetry data were collected. Post-treatment technical and clinical outcomes were analyzed as well as overall survival; finally several factors potentially influencing survival were analyzed. RESULTS: In total 88 patients were selected for angiographic workup; 71 patients (81%) finally underwent catheter-directed (90)Y microsphere infusion into the hepatic artery 25 days (standard deviation 13 days) after angiographic workup. Median infused activity was 1809 MBq; 30-day toxicity included: fatigue (n = 39; 55%), abdominal discomfort (n = 33; 47%), nausea (n = 5; 7%), fever (n = 14; 20%), diarrhea (n = 6; 9%), liver function abnormalities and elevated bilirubin (transient) (n = 3; 4%). Gastric ulcer was found in five patients (7%). A late complication was radioembolization-induced portal hypertension (REIPH) in three patients (4%). Median time to progression in the liver was 4.4 months. Estimated survival at six and 12 months was 65% and 30%, respectively, with a 50% estimated survival after 8.0 months in this group of chemorefractory patients. Prognostic factors for worse survival were high preprocedural bilirubin, alkaline phosphatase and tumor volume levels. CONCLUSION: (90)Y microsphere radioembolization for chemorefractory colorectal liver metastases has an acceptable safety profile with a 50% estimated survival after 8.0 months. Pretreatment high bilirubin, alkaline phosphatase and tumor volume levels were associated with early death.
BACKGROUND: The purpose of this study was to retrospectively assess the technical and clinical outcomes, overall survival and prognostic factors for prolonged survival after yttrium-90 ((90)Y) radioembolization as a salvage therapy for patients with chemorefractory liver-only or liver-dominant colorectal metastases. MATERIAL AND METHODS: From January 2005 to January 2014, all the patients selected for (90)Y radioembolization to treat chemorefractory colorectal liver metastases were identified. Demographic, laboratory, imaging and dosimetry data were collected. Post-treatment technical and clinical outcomes were analyzed as well as overall survival; finally several factors potentially influencing survival were analyzed. RESULTS: In total 88 patients were selected for angiographic workup; 71 patients (81%) finally underwent catheter-directed (90)Y microsphere infusion into the hepatic artery 25 days (standard deviation 13 days) after angiographic workup. Median infused activity was 1809 MBq; 30-day toxicity included: fatigue (n = 39; 55%), abdominal discomfort (n = 33; 47%), nausea (n = 5; 7%), fever (n = 14; 20%), diarrhea (n = 6; 9%), liver function abnormalities and elevated bilirubin (transient) (n = 3; 4%). Gastric ulcer was found in five patients (7%). A late complication was radioembolization-induced portal hypertension (REIPH) in three patients (4%). Median time to progression in the liver was 4.4 months. Estimated survival at six and 12 months was 65% and 30%, respectively, with a 50% estimated survival after 8.0 months in this group of chemorefractory patients. Prognostic factors for worse survival were high preprocedural bilirubin, alkaline phosphatase and tumor volume levels. CONCLUSION: (90)Y microsphere radioembolization for chemorefractory colorectal liver metastases has an acceptable safety profile with a 50% estimated survival after 8.0 months. Pretreatment high bilirubin, alkaline phosphatase and tumor volume levels were associated with early death.
Authors: K J Paprottka; F Schoeppe; M Ingrisch; J Rübenthaler; N N Sommer; E De Toni; H Ilhan; M Zacherl; A Todica; P M Paprottka Journal: Eur J Nucl Med Mol Imaging Date: 2017-02-14 Impact factor: 9.236
Authors: E Janowski; O Timofeeva; S Chasovskikh; M Goldberg; A Kim; F Banovac; D Pang; A Dritschilo; K Unger Journal: Oncol Rep Date: 2016-11-29 Impact factor: 3.906
Authors: Thomas Walter; Neil S Hawkins; Richard F Pollock; Fabien Colaone; Suki Shergill; Paul J Ross Journal: J Cancer Res Clin Oncol Date: 2020-07-27 Impact factor: 4.553
Authors: S C Ebbers; B Kunnen; B J van Nierop; J L M Bemelmans; G C Krijger; M G E H Lam; A J A T Braat Journal: Cardiovasc Intervent Radiol Date: 2020-05-20 Impact factor: 2.740
Authors: Brigitte Maximiliana Aarts; Elisabeth Geneviève Klompenhouwer; Raphaëla Carmen Dresen; Christophe Michel Albert Louis Omer Deroose; Regina Gien Hoa Beets-Tan; Kevin Punie; Patrick Neven; Hans Wildiers; Geert Maleux Journal: Radiol Oncol Date: 2020-01-21 Impact factor: 2.991